Open AccessRadiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy
Author(s) -
P. August Schubiger,
Jürgen Grünberg,
Simon M. Ametamey,
Michael Honer,
Elisa García-Garayoa,
Peter Bläuenstein,
Robert Waibel,
Ilse NovakHofer,
Roger Schibli
Publication year - 2004
Publication title -
chimia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/000942904777677489
Subject(s) - positron emission tomography , molecular imaging , medicine , pet imaging , radionuclide therapy , nuclear medicine , medical physics , biology , in vivo , microbiology and biotechnology
The research and development of smart radiodrugs is the goal of the Center of Radiopharmaceutical Science of ETH, PSI, and USZ. Positron Emission Tomography (PET) allows the non-invasive visualization of biochemical processes within the body. Radiolabeled PET-tracers allow the study of neurophysiological diseases like Alzheimer, Parkinson's disease or the imaging of metastatic tumors. PET-techniques are nowadays an important part of routine nuclear medicine diagnosis. Tumor-cell targeting biomolecules (e.g. antibodies or peptides) coupled to therapeutic radionuclides can sterilize the malignant cells while sparing healthy tissue. This so-called targeted radionuclide therapy has made tremendous progress in the recent years and the first approved radiotherapeutics are available for clinical use.